Jianmin Pharmaceutical Group Co (SHSE:600976) Cyclically Adjusted Revenue per Share: ¥20.65 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600976 Jianmin Pharmaceutical Group Co Ltd SHSE:600976
67 GF Score
Price ¥27.72
GF Value ¥38.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Jianmin Pharmaceutical Group Co Cyclically Adjusted Revenue per Share?

Jianmin Pharmaceutical Group Co SHSE:600976 +0.07% 67 Cyclically Adjusted Revenue per Share is ¥20.65 as of Jun. 2026. GuruFocus rates SHSE:600976 with a GF Score™ of 67/100 and a GF Value™ of ¥38.80 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jianmin Pharmaceutical Group Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥4.867. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥20.65 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Jianmin Pharmaceutical Group Co's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jianmin Pharmaceutical Group Co was 8.40% per year. The lowest was 3.80% per year. And the median was 6.60% per year.

As of today (2026-08-27), Jianmin Pharmaceutical Group Co's current stock price is ¥27.72. Jianmin Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥20.65. Jianmin Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is 1.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jianmin Pharmaceutical Group Co was 4.87. The lowest was 1.00. And the median was 2.09.


Jianmin Pharmaceutical Group Co  (SHSE:600976) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jianmin Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.72/20.65
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jianmin Pharmaceutical Group Co was 4.87. The lowest was 1.00. And the median was 2.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jianmin Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Related Terms


Jianmin Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jianmin Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jianmin Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Chart

Jianmin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.19 17.64 18.77 19.75 20.40

Jianmin Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.18 20.39 20.40 20.60 20.65

SHSE:600976 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jianmin Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jianmin Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jianmin Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jianmin Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600976
67GF Score
Jianmin Pharmaceutical Group Co Ltd SHSE:600976
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jianmin Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jianmin Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.867/116.0564*116.0564
=4.867

Current CPI (Jun. 2026) = 116.0564.

Jianmin Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.997 102.400 4.530
201612 3.960 102.600 4.479
201703 3.932 103.200 4.422
201706 5.481 103.100 6.170
201709 4.208 104.100 4.691
201712 3.908 104.500 4.340
201803 3.240 105.300 3.571
201806 3.866 104.900 4.277
201809 3.362 106.600 3.660
201812 3.618 106.500 3.943
201903 3.427 107.700 3.693
201906 3.717 107.700 4.005
201909 4.524 109.800 4.782
201912 2.698 111.200 2.816
202003 2.795 112.300 2.888
202006 3.872 110.400 4.070
202009 3.798 111.700 3.946
202012 5.463 111.500 5.686
202103 5.495 112.662 5.661
202106 6.309 111.769 6.551
202109 5.334 112.215 5.517
202112 4.589 113.108 4.709
202203 6.002 114.335 6.092
202206 6.105 114.558 6.185
202209 6.367 115.339 6.407
202212 5.438 115.116 5.482
202303 6.616 115.116 6.670
202306 7.517 114.558 7.615
202309 6.293 115.339 6.332
202312 7.122 114.781 7.201
202403 6.336 115.227 6.382
202406 6.761 114.781 6.836
202409 5.713 115.785 5.726
202412 4.179 114.893 4.221
202503 5.911 115.116 5.959
202506 6.031 114.907 6.091
202509 4.861 115.471 4.886
202512 5.404 115.832 5.414
202603 5.772 116.303 5.760
202606 4.867 116.056 4.867

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥20.65 mean?
Jianmin Pharmaceutical Group Co (SHSE:600976) has a Cyclically Adjusted Revenue per Share of ¥20.65 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jianmin Pharmaceutical Group Co and its competitors.
Is Jianmin Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share too high?
Jianmin Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is ¥20.65. Overall, Jianmin Pharmaceutical Group Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jianmin Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Jianmin Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share of ¥20.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jianmin Pharmaceutical Group Co and its competitors. Jianmin Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is ¥20.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jianmin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jianmin Pharmaceutical Group Co (SHSE:600976) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.80, compared to a current price of ¥27.72 — trading 28.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥20.65. Jianmin Pharmaceutical Group Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jianmin Pharmaceutical Group Co (SHSE:600976), the current Cyclically Adjusted Revenue per Share is ¥20.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jianmin Pharmaceutical Group Co (SHSE:600976) Overvalued in 2026?

Based on GuruFocus' analysis, Jianmin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥27.72 is trading 28.6% below its estimated GF Value™ of ¥38.80. GuruFocus considers Jianmin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600976:

  • Cyclically Adjusted Revenue per Share: ¥20.65
  • GF Value™: ¥38.80 vs. price of ¥27.72 (28.6% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600976 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jianmin Pharmaceutical Group Co Business Description

Address No. 484 Parrot Avenue, Hanyang District, Wuhan, CHN, 430052
Jianmin Pharmaceutical Group Co Ltd is engaged in the manufacture and distribution of pharmaceutical products. It adheres to the core position of pediatric medicine, gynecological medicine, and special Chinese medicine, it offers products under Jianmin and Longmu brands.
67GF Score

Get the complete analysis for SHSE:600976

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.72
Price
¥38.80
GF Value